z-logo
open-access-imgOpen Access
Targeting Antigens to Dendritic Cell Receptors for Vaccine Development
Author(s) -
Vasso Apostolopoulos,
Theresia Thalhammer,
Andreas G. Tzakos,
Lily Stojanovska
Publication year - 2013
Publication title -
journal of drug delivery
Language(s) - English
Resource type - Journals
eISSN - 2090-3014
pISSN - 2090-3022
DOI - 10.1155/2013/869718
Subject(s) - immune system , antigen , dendritic cell , context (archaeology) , immunotherapy , antigen presenting cell , immunology , t cell , cancer immunotherapy , endocytic cycle , biology , cancer vaccine , antigen presentation , microbiology and biotechnology , cell , endocytosis , paleontology , genetics
Dendritic cells (DCs) are highly specialized antigen presenting cells of the immune system which play a key role in regulating immune responses. Depending on the method of antigen delivery, DCs stimulate immune responses or induce tolerance. As a consequence of the dual function of DCs, DCs are studied in the context of immunotherapy for both cancer and autoimmune diseases. In vaccine development, a major aim is to induce strong, specific T-cell responses. This is achieved by targeting antigen to cell surface molecules on DCs that efficiently channel the antigen into endocytic compartments for loading onto MHC molecules and stimulation of T-cell responses. The most attractive cell surface receptors, expressed on DCs used as targets for antigen delivery for cancer and other diseases, are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom